How Much Did Quincy Bioscience Raise?
Funding & Key Investors

Quincy Bioscience, a Madison, Wisconsin-based biotechnology firm, has secured significant enterprise-level funding, with its total funding reaching $5.2M. The company recently announced a major strategic investment of $5.2M, underscoring its continued growth and market presence in the cognitive health sector. This latest capital infusion is expected to fuel further development and commercialization of its proprietary apoaequorin-based technologies.

What is Quincy Bioscience?

Quincy Bioscience
ManufacturingHealth & Nutrition ProductsRetail

Quincy Bioscience specializes in the discovery, development, and commercialization of novel technologies aimed at supporting cognitive function and addressing age-related memory concerns. The company's unique approach centers on apoaequorin, a protein originally identified in jellyfish, which Quincy Bioscience has patented for its ability to modulate calcium signaling within the body. This protein's role in calcium signaling was recognized with a Nobel Prize in Chemistry in 2008. Quincy Bioscience manufactures apoaequorin in a cGMP compliant facility, ensuring product quality and safety. The flagship consumer brand, Prevagen®, incorporates apoaequorin and has demonstrated efficacy in improving memory and recall in published studies. Prevagen® has achieved significant market penetration, becoming the number one selling brain support supplement in U.S. chain pharmacies, according to A.C. Nielsen data. The company's rapid expansion was recognized with a #398 ranking on the Inc. 500 list of fastest-growing private companies in 2012.

How much funding has Quincy Bioscience raised?

Quincy Bioscience has raised a total of $5.2M across 1 funding round:

2009

Unspecified

$5.2M

Unspecified (2009): $5.2M, investors not publicly disclosed

What's next for Quincy Bioscience?

With a substantial enterprise-level funding round and a recent strategic investment, Quincy Bioscience is well-positioned for its next phase of growth. The company's focus on apoaequorin, a scientifically validated ingredient with demonstrated consumer demand, provides a strong foundation. Future strategic initiatives will likely involve expanding the Prevagen® product line, exploring new therapeutic applications for apoaequorin, and potentially increasing market reach through further distribution partnerships or international expansion. The company's commitment to research and development, coupled with its established market position, suggests a trajectory aimed at solidifying its leadership in the cognitive health and wellness market.

See full Quincy Bioscience company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Manufacturing industry

Industrial Machinery & EquipmentManufacturing
Building MaterialsManufacturingConstruction ManagementConstruction
ManufacturingPlastic, Packaging & Containers
ManufacturingTest & Measurement EquipmentIndustrial Machinery & Equipment

Frequently Asked Questions Regarding Quincy Bioscience Financial Insights

What are the most recent funding rounds that Quincy Bioscience has completed, and what were the funding rounds?
Quincy Bioscience has recently completed 1 funding rounds: Unspecified on May 14, 2009.
What is the total amount of funding Quincy Bioscience has raised to date?
Quincy Bioscience has raised a total of $5.2M in funding to date.
How many funding rounds has Quincy Bioscience completed?
Quincy Bioscience has completed 1 funding rounds.
How much funding did Quincy Bioscience raise in its most recent funding round?
Quincy Bioscience raised $5.2M in its most recent funding round.
Which was the largest funding round in Quincy Bioscience's history?
The largest funding round in Quincy Bioscience's history was $5.2M.
See more information about Quincy Bioscience